Lower Costs, More Cures Act of 2019

Hozzl · 2022-10-28T01:46:01Z

Explore the details of House Bill 19 Lower Costs, More Cures Act of 2019 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:46 AM

Congressional Summary of HR 19

Lower Costs, More Cures Act of 2019

This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.

The bill generally

limits payment amounts for drugs and biologics under Medicare medical services,
reduces cost-sharing under the Medicare prescription drug benefit,
modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
establishes several reporting requirements for drug manufacturers with respect to drug prices.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 19

Bill HR 19 is currently in the status of Bill Introduced since December 9, 2019. Bill HR 19 was introduced during Congress 116 and was introduced to the House on December 9, 2019. Bill HR 19's most recent activity was Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. as of December 19, 2019

Bipartisan Support of Bill HR 19

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

147

Democrat Cosponsors

Republican Cosponsors

147

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 19

Primary Policy Focus

Health

Potential Impact Areas

Administrative law and regulatory proceduresAdministrative remediesAdvisory bodiesAppropriationsBiological and life sciencesBusiness recordsCancerChemistryChild healthCivil actions and liabilityCompetition and antitrustCongressional oversightConsumer affairsCorporate finance and managementCosmetics and personal careDepartment of Health and Human ServicesDigestive and metabolic diseasesDrug safety, medical device, and laboratory regulationDrug therapyExecutive agency funding and structureFederal Trade Commission (FTC)Food and Drug Administration (FDA)Fraud offenses and financial crimesGeneticsGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth personnelHealth programs administration and fundingHealth technology, devices, suppliesHome and outpatient careHospital careImmunology and vaccinationIncome tax deductionsIncome tax exclusionInflation and pricesIntellectual propertyIntergovernmental relationsJudicial review and appealsLicensing and registrationsManufacturingMarketing and advertisingMedicaidMedical educationMedical researchMedical tests and diagnostic methodsMedicareOffice of the U.S. Trade RepresentativePrescription drugsProduct development and innovationPublic participation and lobbyingResearch and developmentRetail and wholesale tradesState and local government operationsTrade agreements and negotiationsUser charges and feesWomen's health

Alternate Title(s) of Bill HR 19

Lower Costs, More Cures Act of 2019To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes.Lower Costs, More Cures Act of 2019Over-the-Counter Monograph User Fee Act of 2019Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019

Start holding our government accountable!